多西他赛联合顺铂治疗蒽环类耐药的晚期三阴性乳腺癌的临床观察

The Clinical Observation of Docetaxel plus Cisplatin Chemotherapy for Patients with Advanced Triple-negative Breast Cancer Failed to Anthracycline

目的观察多西他赛联合顺铂治疗蒽环类耐药的晚期三阴性乳腺癌的疗效及安全性。方法 18例蒽环类耐药的晚期三阴性乳腺癌患者给予多西他赛75 mg·m-2,静滴,d1;顺铂25 mg·m-2,静滴,d1～3,3周重复,治疗后评价客观疗效及毒副反应。结果 18例患者均可评价疗效,PR 7例(38.9%),SD 8例(44.4%),PD 3例(16.7%),总有效率为38.9%。中位疾病进展时间为6.5个月。毒副反应主要为骨髓抑制和胃肠道反应。结论多西他赛联合顺铂方案治疗蒽环类耐药的晚期三阴性乳腺癌疗效确切,安全性较好。

Objective To evaluate the efficacy and safety of docetaxel plus cisplatin chemotherapy for patients with advanced triple-negative breast cancer failed to anthracycline. Methods The 18 patients with advanced triple- negative breast cancer failed to anthracycline were treated： docetaxel 75 mg ·m^-2,intravenously guttae, d1 ; cisplatin 25 mg·m^-2, intravenously guttae, d1-3 ,3 weeks were 1 cycle. After chemotherapy, the efficacy and toxicities were evaluated. Results Of all the 18 cases, PR was observed in the 7 cases （ 38.9% ）, SD in the 8 cases （44.4%） ,PD in the 3 cases （16.7%） ,the overall response rate was 38.9%. The median time to progression was 6.5 months. Myelosuppression and gastrointestinal reaction were the most common toxicities. Conclusion The do- cetaxel plus cisplatin chemotherapy is effective and safety for patients with advanced triple-negative breast cancer failed to anthracycline.